410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

409O N (%) Total (N45) Any grade Grade 3 Obrixtamig or ezabenlimab-related AEs* 44 (98) 23 (51) Cytokine release syndrome (CRS) 35 (78) 0 (0) Dysgeusia 20 (44) 0 (0) Fatigue 17 (38) 2 (4) Lymphocyte count decreased 16 (36) 15 (33) Decreased appetite 16 (36) 1 (2) Nausea 10 (22) 0 (0) Rash 9 (20) 0 (0) Obrixtamig-related potential neurological toxicity including ICANS 6 (13) 3 (7) ICANS 2 (4) 2 (4) Immune-mediated encephalopathy 1 (2) 1 (2) Confusional state 1 (2) 0 (0) Disturbance in attention 1 (2) 0 (0) Lethargy 1 (2) 0 (0) Leukoencephalopathy 1 (2) 0 (0) *In 20% of pts. Grouped term.Conclusions: Obrixtamig + ezabenlimab showed manageable safety and tolerability in pts with pretreated DLL3+ NECs.Encouraging efficacy was observed particularly at higher doses of obrixtamig and in pts with SCLC.Clinical trial identification: NCT05879978.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106724
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

D. Spigel, W.C.V. Lai, K.H. Lee, Y. Zenke et al.
ESMO Open
Lung Cancer Research Studies
article

410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

D. Spigel, W.C.V. Lai, K.H. Lee, Y. Zenke, J. Fang, L. Paz-Ares, S. Novello, B.C. Cho, P. Chugh, E.L. Buchmeier, S. Sezgin Goksu, Y. Chen, R. Bernabe Caro, M. Ozguroglu, H. Xiong, K. Laktionov, N. Reinmuth, I. Okamoto, Q. Wang, S. Senan
article en

Abstract

409O N (%) Total (N45) Any grade Grade 3 Obrixtamig or ezabenlimab-related AEs* 44 (98) 23 (51) Cytokine release syndrome (CRS) 35 (78) 0 (0) Dysgeusia 20 (44) 0 (0) Fatigue 17 (38) 2 (4) Lymphocyte count decreased 16 (36) 15 (33) Decreased appetite 16 (36) 1 (2) Nausea 10 (22) 0 (0) Rash 9 (20) 0 (0) Obrixtamig-related potential neurological toxicity including ICANS 6 (13) 3 (7) ICANS 2 (4) 2 (4) Immune-mediated encephalopathy 1 (2) 1 (2) Confusional state 1 (2) 0 (0) Disturbance in attention 1 (2) 0 (0) Lethargy 1 (2) 0 (0) Leukoencephalopathy 1 (2) 0 (0) *In 20% of pts. Grouped term.Conclusions: Obrixtamig + ezabenlimab showed manageable safety and tolerability in pts with pretreated DLL3+ NECs.Encouraging efficacy was observed particularly at higher doses of obrixtamig and in pts with SCLC.Clinical trial identification: NCT05879978.

ESMO OpenVol. 11
Cancer Treatment Centers of America (US), Yonsei University (KR), Akdeniz University (TR), Peking University (CN), Zhengzhou University (CN), Peking University Cancer Hospital (CN), Kyushu University Hospital (JP), Ministry of Health (ES), Sarah Cannon (US), Hospital Universitario 12 De Octubre (ES), Istanbul University-Cerrahpaşa (TR), AstraZeneca (Switzerland) (CH), German Center for Lung Research (DE), Henan Cancer Hospital (CN), National Cancer Center Hospital East (JP), AstraZeneca (United States) (US), Amsterdam University Medical Centers (NL), Hospital Universitario Virgen del Rocío (ES), University Hospital Cologne (DE), Ospedale San Luigi Gonzaga (IT), Chungbuk National University Hospital (KR), University of Turin (IT), Vrije Universiteit Amsterdam (NL)
Openalex Percentile: Top 18%
Lung Cancer Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.